Email: mark.wilcox@nhs.net

Research profile and key clinical specialties

Professor Wilcox is Chair of PHE’s Rapid Review Panel (reviews the utility of infection prevention & control products for the NHS), and is a member of the NHS Antimicrobial Resistance Programme Board.

Since the pandemic, he is a member of UK Scientific Advisory Group on Emergencies (SAGE, COVID-19; and chairs one of its subgroups on Nosocomial Infection), and is co-chair of the UK Technical Validation Group for COVID-19 tests.

From 2017-21 he was a member of the Medical Research Council’s Infections and Immunity Board. From 2017, he was seconded one day per week to NHS Improvement to support the delivery of the new national target to reduce healthcare associated Gram-negative blood stream infections in England.

He was the Deputy Chair of the UK Department of Health’s Antimicrobial Prescribing Resistance and Healthcare Associated Infection (APRHAI) Committee up until 2018; and still attends this committee.

Two key publications

• Rooney CM, … Wilcox MH, Chilton CH. Dissemination of multiple carbapenem resistance genes in an in vitro gut model simulating the human colon. J Antimicrob Chemother 2019;74:1876-1883.
• Buckley AM, … Wilcox MH. Trehalose-Induced Remodelling of the Human Microbiota Affects Clostridioides difficile Infection Outcome in an In Vitro Colonic Model: A Pilot Study. Front Cell Infect Microbiol 2021;11:670935.

Possible PhD projects

Use of gut models to determine:

• the effects of antimicrobial exposure on the gut microbiome;
• the emergence of resistance. 

——————–

Keywords: NHS Antimicrobial Resistance Programme Board, APRHAI, nosocomial, infection, Gram-negative blood, carbapenem, vitro colonic, Mark, Wilcox, Leeds

Related